Vitrafy Life Sciences Limited (ASX:VFY)
Australia · Delayed Price · Currency is AUD | Market Cap | 289.56M +212.8% |
| Revenue (ttm) | 209.00K -80.1% |
| Net Income | -16.17M |
| EPS | -0.25 |
| Shares Out | 76.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,699 |
| Open | 3.750 |
| Previous Close | 3.800 |
| Day's Range | 3.750 - 3.920 |
| 52-Week Range | 1.160 - 4.660 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 4.98 (+30.71%) |
| Earnings Date | Aug 4, 2026 |
About Vitrafy Life Sciences
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquacu... [Read more]
Financial Performance
In fiscal year 2026, Vitrafy Life Sciences's revenue was 208,997, a decrease of -80.05% compared to the previous year's 1.05 million. Losses were -16.17 million, -50.56% less than in 2025.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VFY stock is "Strong Buy." The 12-month stock price target is $4.98, which is an increase of 30.71% from the latest price.
News
Vitrafy Life Sciences Earnings Call Transcript: H2 2026
Transformational year marked by major milestones in blood and animal markets, strong revenue growth, and successful U.S. expansion. FDA device registration and further U.S. market penetration are key near-term goals, supported by a robust cash position.
Vitrafy Life Sciences Slides: H2 2026
Vitrafy Life Sciences has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 3, 2026.
Vitrafy Life Sciences Annual report: H2 2026
Vitrafy Life Sciences has published its H2 2026 annual report on August 3, 2026.
Vitrafy Life Sciences Slides: Investor presentation
Vitrafy Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Vitrafy Life Sciences Slides: Investor presentation
Vitrafy Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Vitrafy Life Sciences Transcript: Study result
Phase II results show 94% post-thaw recovery for cryopreserved platelets using a no-wash protocol, validated by the U.S. Army. The approach reduces toxicity and operational complexity, supporting rapid deployment and stockpiling for trauma response in both military and civilian settings.
Vitrafy Life Sciences Slides: Study result
Vitrafy Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Vitrafy Life Sciences Earnings Call Transcript: Q3 2026
Strong progress in blood, cell and gene therapy, and animal reproduction verticals, with phase II U.S. military blood platelets testing completed and positive results driving commercial interest. Cash position remains robust at AUD 18.5 million, supporting expansion and regulatory milestones.
Vitrafy Life Sciences Earnings release: Q3 2026
Vitrafy Life Sciences released its Q3 2026 earnings on April 27, 2026, summarizing the period's financial results.
Vitrafy Life Sciences Slides: Q3 2026
Vitrafy Life Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 27, 2026.
Vitrafy Life Sciences Transcript: NWR Virtual Healthcare Conference
Cryopreservation underpins critical healthcare sectors but relies on outdated technology, prompting the development of a smart, connected ecosystem targeting animal reproduction, blood products, and cell/gene therapy. Strategic partnerships, U.S. expansion, and FDA approval are set to drive growth.
Vitrafy Life Sciences Slides: NWR Virtual Healthcare Conference
Vitrafy Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Vitrafy Life Sciences Earnings Call Transcript: H1 2026
Secured first commercial contract in animal reproduction, driving immediate revenue and validating strategy. Strong cash position supports US expansion, with key milestones ahead in human health and FDA registration. Significant commercial interest in both defense and civilian health sectors.
Vitrafy Life Sciences Quarterly report: H1 2026
Vitrafy Life Sciences has published its H1 2026 quarterly earnings report on February 3, 2026.
Vitrafy Life Sciences Slides: H1 2026
Vitrafy Life Sciences has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 3, 2026.
Vitrafy Life Sciences Earnings Call Transcript: Q2 2026
Secured a major commercial agreement with IMV, expanded U.S. operations, and maintained a strong cash position nearing AUD 23 million. Focus remains on executing commercial deals, expanding manufacturing, and targeting high gross margins through cost reductions.
Vitrafy Life Sciences Earnings release: Q2 2026
Vitrafy Life Sciences released its Q2 2026 earnings on January 28, 2026, summarizing the period's financial results.
Vitrafy Life Sciences Slides: Q2 2026
Vitrafy Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 28, 2026.
Vitrafy Life Sciences Press release: Collaboration
Vitrafy Life Sciences issued a press release on January 14, 2026, disclosing material business information to investors.
Vitrafy Life Sciences Slides: Collaboration
Vitrafy Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Vitrafy Life Sciences Transcript: Bell Potter Healthcare Conference 2025
Breakthrough cryopreservation technology is set to transform animal and human health markets, with strong U.S. Army trial results, robust IP, and a managed service model driving rapid scaling. Commercial focus is on blood platelets and cell/gene therapy, with North American expansion underway.
Vitrafy Life Sciences Transcript: AGM 2025
Leadership transition and strategic focus on North American expansion, commercialization, and operational scaling were highlighted. Financial discipline remains a priority, with strong cash reserves and grant support. All AGM resolutions passed, and a live demonstration of the Guardian device marked a key milestone.
Vitrafy Life Sciences Slides: FY 2025
Vitrafy Life Sciences has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 19, 2025.
Vitrafy Life Sciences Earnings Call Transcript: Q1 2026
Major milestones achieved with the VCU2 device and LifeChain software, supporting immediate market entry and strong commercial pipeline. Cash position remains robust, with a runway into 2027 and key regulatory and commercialization milestones targeted for 2026.
Vitrafy Life Sciences Earnings release: Q1 2026
Vitrafy Life Sciences released its Q1 2026 earnings on October 22, 2025, summarizing the period's financial results.